Introduction {#Sec1}
============

Sedation is an integral part of intensive care practice to minimise patient discomfort and anxiety, facilitate mechanical ventilation and allow essential intensive care procedures \[[@CR1], [@CR2]\]. Complications associated with sedative prescription and in particular deep sedation with adverse outcomes have been well described \[[@CR3], [@CR4]\]. Reports of shorter ventilation time, shorter ICU stay and attenuation of delirium with protocols targeting light sedation \[[@CR5]--[@CR8]\] highlight the need to avoid deep sedation proactively \[[@CR9]\].

There are no reliable data on the compliance of intensive care clinicians with published guidelines or the implementation of protocols to promote light sedation \[[@CR10]\]. A meta-analysis has reported that most sedation trials failed to achieve optimal sedation, and more than two-thirds of studies reported inappropriate deep sedation \[[@CR11]\]. Sedation practice surveys did not assess patients longitudinally and are therefore unable to draw conclusions on the incidence of deep sedation or its association with relevant outcomes \[[@CR12]--[@CR14]\].

Randomised clinical trials and observational cohort studies have largely not accounted for the early prescription of sedative agents or the early depth of sedation, in particular in the first 48 h after the initiation of mechanical ventilation. Early deep sedation is therefore a risk factor that may be overlooked while clinicians' attention focuses on more pressing issues and priorities. The occurrence of early deep sedation, therefore, can have a significant confounding effect on the results of sedation trials if not taken into consideration.

The Australian New Zealand sedation practice in intensive care evaluation (ANZ SPICE) study \[[@CR15]\] revealed that early sedation depth predicts important outcomes such as mortality. To assess the strength of this relationship outside an ANZ model of care, we replicated the ANZ SPICE in Malaysian ICUs. In this prospective, longitudinal, multicentre cohort study, we assessed current sedation practice and the prevalence of deep sedation, particularly early after initiation of mechanical ventilation, and quantified the relationship between early deep sedation and important clinical outcomes including time to extubation, delirium and hospital and 180-day mortality.

Materials and methods {#Sec2}
=====================

Study design and process {#Sec3}
------------------------

We conducted a multicentre, prospective, longitudinal, observational, non-interventional cohort study in 11 ICUs (8 public, 2 university and 1 tertiary specialist centres) in Malaysia from March to July 2011 using the ANZ SPICE protocol \[[@CR15]\]. All participating ICUs were managed by full-time intensivists and/or anaesthesiologists with a 24/7 on-duty senior medical officer. In ventilated patients, the nurse:patient ratio was 1:2 in most ICUs. The study was approved by The National Medical Research Register and consent waived by the institutional ethics committee at participating sites.

The study was conducted in collaboration with the ANZ Intensive Care Research Centre (ANZIC RC) and the Monash University Centre for Clinical Research Excellence in Therapeutics. A streamlined case report form with Optical Recognition Software was used and sent to the ANZIC RC for data entry, data queries and analysis.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Patients were included if they had been ventilated within the previous 24 h, were receiving continuous or intermittent sedative and/or analgesic medication and were expected to be ventilated for longer than 24 h. Patients were excluded if they were \<18 years, had proven or suspected neurological impairment, psychiatric illness, burns, dementia, palliative care or were unable to communicate with carers/investigators because of language difficulty. No centre recruited more than 30 patients.

Study logistics {#Sec5}
---------------

Principal investigators, research staff and senior nurses at each participating centre were trained in the study procedures, including bedside twin assessment of patients using the Richmond Agitation and Sedation Scale (RASS) \[[@CR16]\] and the confusion assessment method for intensive care (CAM-ICU) \[[@CR17]\]. Assessors were allowed to use local dialects (English, Malay, Hindi, Mandarin or Cantonese) to communicate with patients. To conduct the inattention (feature II) part of the CAM-ICU in patients who had difficulty with the alphabet, numbers were used (ten random numbers where the number 3 was repeated four times) instead of the (SAVEAHAART) phrase \[[@CR18]\]. CAM-ICU was conducted ONLY if patients were in a RASS range of −2 to +1 (lightly sedated).

Definitions and data collection methods {#Sec6}
---------------------------------------

Relevant baseline demographic data including hospital and ICU admission details and Acute Physiology and Chronic Health Evaluation II (24-h APACHE II) scores were collected \[[@CR19]\].

Patients were followed from ICU admission to ICU discharge or 28 days in the ICU, which ever came first. The first 48 h following initiation of mechanical ventilation was considered "early" and \>48 h the "subsequent" period. RASS was assessed every 4 h and CAM-ICU assessed daily by trained nurses or principal investigators. Patients in a RASS range of −2 to +1 were considered lightly sedated, RASS range of −3 to −5 deeply sedated and \>2 agitated. Patients were considered delirious if the CAM-ICU was positive. Patients were considered coma and delirium free if they had a RASS above −3 with a negative CAM-ICU score. Administration details and dosage of all sedative, analgesic and adjunct medications (intravenous infusion or bolus) were collected daily. Survival status at ICU and hospital discharge and at 180 days was collected. Only patients who reside in Malaysia were followed for 180-day mortality.

Statistical analysis {#Sec7}
--------------------

The statistical analysis was modelled on that used in the ANZ SPICE \[[@CR15]\] and independently conducted at the ANZIC RC, Monash University, Centre for Clinical Research Excellence in Therapeutics.

### Sample size {#Sec8}

Based on the ANZIC SPICE data, 260 patients would have 90 % power with a two-sided *p* value of 0.05 to detect a difference of 2 in the number of times deep sedation was reported in the first 48 h between patients who died or survived. This would also allow 80 % power to identify point estimates within 5 % of the true value of an event assuming it occurred in 10 % of patients.

### Statistical analysis {#Sec9}

All patients were included in the analysis. Comparisons of proportions were performed using chi-square tests for equal proportions or Fisher's exact tests where appropriate. Normally distributed continuous variables were compared using Student's t tests. Non-normally distributed variables were compared using Wilcoxon rank-sum tests.

RASS scores were treated as ordinal data; however, the RASS range of deep sedation (−3 to −5) was considered a continuous variable with every additional RASS level in the deep sedation range adding to the intensity of sedation depth. Early deep sedation was the primary exposure variable in the time to event analysis of outcomes occurring after 48 h: time to extubation, time to subsequent delirium, time to hospital death and 180-day mortality. Time to event analysis was performed using Cox proportional hazard regression and reported as hazard ratios (95 % CI) and as Kaplan-Meier curves with a corresponding log-rank test. All patients with an ICU stay greater than 48 h were included in the Kaplan-Meier estimates with conventional censoring at the time of death. Adjustment of observed effects due to known or suspected potential confounders was undertaken using multivariable analysis using a list of a priori defined covariates comprising APACHE III diagnosis (cardiac, respiratory, gastrointestinal, sepsis or other), age, sex, APACHE II score, operative admission (surgical), elective admission and the cumulative doses of midazolam and dexmedetomidine, and the use of vasopressors and dialysis within the first 48 h of admission. All patients with ICU lengths of stay less than 48 h were excluded from the multivariate analysis. A two-sided *p* value of 0.05 was considered to be statistically significant. Analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and STATA version 11.0 (StataCorp LP College Station, TX, USA).

Results {#Sec10}
=======

Patients' demographics and baseline characteristics {#Sec11}
---------------------------------------------------

We enrolled 259 patients; the main source of admission was from the general ward and emergency department (166) 64 %, with only (35) 13.5 % of patients admitted after elective surgery. Mortality at 6 months was 46.4 %; loss to follow-up occurred in (22) 8.5 % patients. Baseline demographics and clinical characteristics for the primary cohort and for patients who were lightly sedated versus those who were deeply sedated at 48 h are shown in Table [1](#Tab1){ref-type="table"}.Table 1Patients' demographics and clinical characteristicsPatients' characteristicsPrimary cohort (*n* = 259)Divided by sedation level at 48 h in patients with ICU stay \>48 hLightly sedated (*n* = 45)Deeply sedated (*n* = 209)*P* valueAge, mean (SD), years53.1 ± 15.953.6 ± 13.953.2 ± 16.30.87Male (*n*)  %(162) 62.5 %(25) 55.5 %(134) 64.1 %0.28Weight, mean (SD), kg68.2 ± 19.872.7 ± 22.267.4 ± 19.40.10APACHE II score, mean (SD)21.3 ± 8.220.1 ± 7.821.6 ± 8.30.24Operative admission diagnosis (*n*)  %(83) 32.0 %(18) 40.7 %(65) 31.1 %0.25Respiratory failure admission diagnosis^a^ (*n*)  %(66) 25.5 %(13) 28.9 %(51) 24.4 %0.53Cardiovascular admission diagnosis^a^ (*n*)  %(39) 15.4 %(11) 24.4 %(29) 13.9 %0.08Vasopressors infusions (*n*)  %(209) 80.7 %(28) 62.2 %(164) 78.4 %0.021Renal replacement therapy (*n*)  %(73) 28.2 %(7) 15.6 %(43) 20.6 %0.44Tracheostomy after ICU admission (*n*)  %(36) 14 %(7) 15.6 %(28) 13.4 %0.71Time to tracheostomy, median (IQR) days9.35 (5.63--15.34)11 (5.67--16)9.35 (5.63--13.7)0.86Ventilation days, median (IQR)4.96 (2.99--8.8)3.95 (2.7--6.9)6.69 (4--11.7)0.00828-Day coma and delirum-free days24 (0--26)28 (26--28)23 (0--26)\<0.0001ICU length of stay, median (IQR) days7.19 (4.8--11)6.52 (4.83--6.69)7.7 (4.95--11.57)0.35Hospital length of stay, median (IQR) days16.4 (10.0--30.7)17.6 (12.7--32.2)16.5 (9.5--28.9)0.08ICU mortality (*n*)  %(66) 25.5 %(3) 6.7 %(63) 30.1 %0.001Hospital mortality (*n*)  %(82) 31.7 %(6) 13.4 %(76) 36.4 %0.003180-day mortality (*n*)  %(110/237) 46.4 %(10/41) 24.4 %(100/192) 52.1 %0.001*n* Number, *SD* standard deviation, *IQR* interquartile range, *APACHE II* Acute Physiologic Assessment and Chronic Health Evaluation^a^APACHE III diagnostic codes \[[@CR19]\]

Sedative and analgesic prescription {#Sec12}
-----------------------------------

### Overall therapy {#Sec13}

Patients were followed up to a total of 2,657 ICU days, of which 72.8 % (1,935) were ventilated days and 91.8 % (2,439) days in which sedative and/or analgesic medications were administered. Midazolam was the predominant sedative agent given to 93 % (241) of patients on 39.6 % (966) of study days. Propofol prescription was significantly less and only given to 74 (28 %) (*P* \< 0.0001 compared with midazolam) of patients on 7.5 % (183) of study days. The primary analgesics used were morphine and fentanyl in 77.6 % (199) and 60.2 % (156) (*P* \< 0.001) of patients respectively. Dexmedetomidine was given to 29.3 % (76) of patients. Adjunct medications such as haloperidol, diazepam and ketamine were uncommonly used in 8.9 % (21), 2.3 % (6) and 5.8 % (14) of patients respectively.

### Prescription over first 48 h {#Sec14}

In the 48 h following initiation of mechanical ventilation, most patients received midazolam \[88.4 % (229)\] and/or morphine \[71.4 % (185)\] and/or fentanyl \[40.5 %(105)\]. Dexmedetomidine and propofol were given to 16.2 % (42) and 10 % (26) of patients respectively. Table [2](#Tab2){ref-type="table"} shows the sedative, analgesic and adjunct drug administration in the first 48 h and throughout the study period including cumulative per patient, per day dosage and the number of prescription days for each agent.Table 2Sedative, analgesic and adjunct medications givenDrugs givenDuring the first 48 hDuring entire studyICU days 518 *n* (%)Dose^a^ (patient^−1^ day^−1^)ICU days 2,439 *n* (%)Dose^a^ (patient^−1^ day^−1^)Duration treatment days^b^Midazolam (mg)389 (75.1 %)28 (12--58)966 (39.6 %)31 (12--66)3.37 (3.4)Propofol (mg)36 (6.9 %)240 (100--680)183 (7.5 %)350 (100--800)0.71 (1.4)Morphine (mg)327 (63.1 %)24.5 (12.54)773 (31.7 %)25 (10--51)2.99 (3.23)Fentanyl168 (32.4 %)290 (95--620)771 (31.6 %)450 (200--780)2.97 (4.19)Dexmedetomidine65 (12.5 %)1.93 (0.9--4.3)334 (13.7 %)3.96 (1.98--7.2)1.29 (2.67)Ketamine (mg)16 (3.1 %)390 (157--750)46 (1.9 %)1,374 (315--3,840)^c^0.18 (0.84)Haloperidol (mg)6 (1.2 %)7.5 (2.2--13.5)51 (2.1 %)15 (5--46)^c^0.19 (0.79)Diazepam (mg)2 (0.4 %)4.2 (2.2--6)20 (0.8 %)21 (10--15)^c^0.08 (0.69)^a^Cumulative median (IQR) dose mg (when stated), µg (dexmedetomidine and fentanyl) patient^−1^ day^−1b^Mean (SD)^c^Cumulative dose patient^−1^

Early and subsequent sedation level {#Sec15}
-----------------------------------

Over a total of 2,657 ICU study days, 13,836 RASS assessments were made. At first assessment, 71 % (182/257) of patients were in the deep sedation range (RASS −3 to −5). Of all RASS assessments conducted early (first 48 h), 58 % (1,658) were in the deep sedation range, 39.3 % (1,124) in the light sedation range (−2 to +1) and 2.8 % (80) in the RASS range of 2--4. During the first 48 h after initiation of mechanical ventilation, the median (IQR) of all RASS scores was −3 \[−4−(−1)\]. At the end of 48 h, 61 % (159) of patients were still deeply sedated.

After 48 h and subsequently throughout the study period, the median (IQR) RASS scores were −1 \[−3−0\], with 34 % (4,528/13,319) of RASS assessments in the deep sedation range, 62.4 % (8,311/13,319) in the lightly sedated range, and only 3.5 % (466/13,319) RASS assessments were between 2 and 4. There was a significant difference in the intensity of sedation scored in the first 48 h compared with subsequent study days (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1RASS assessments during early (first 48 h) and subsequent study days. During the first 48 h following initiation of mechanical ventilation, 2,859 RASS assessments were conducted, of which 58 % (1,658) were in the −3 to −5 range compared to 34 % (4,258/13,319) in the −2 to +1 range (*P* \< 0.0001). There was a significant increase in the RASS score of 0 (Calm) after the first 48 h \[(4,688/13,319) 35.2 % versus (323) 11.3 % (*P* \< 0.0001) in the first 48 h\]

The main reported indications for deep sedations were controlled ventilation 64.9 % (288/444) and concurrent muscle relaxation and severe agitation 35.1 % (156/444) of days where an indication for deep sedation was present. Clinicians prescribed a sedation target on 22.8 % (3,074/13,481) of occasions, and the target was achieved in 47 % (1,446) of assessments. Deliberate cessation of all sedatives and analgesics occurred on 20 % (485/24,240) of study days; however, routine daily sedation interruption was rarely implemented in only 2.3 % (56) of days.

Throughout the study period, neuromuscular blockers were used on 4.1 % (100) of ICU days, while physical restraints were used on 21.1 % (515) of days. Self extubation was recorded in 0.4 % (10) of episodes.

Occurrence of delirium {#Sec16}
----------------------

Delirium (positive CAM-ICU during RASS −2 to +1) was reported in 27.4 % (20/73) of patients at first assessment and in 44 % (114) of patients throughout the study period for a median (IQR) of 2 (1--4) days. In patients who stayed \>8 days in the ICU, delirium was present in 50 % (33/66) and 68.9 % (31/45) of patients who stayed in the ICU longer than 14 days. Coma and delirium-free days at 28 days were significantly more in patients lightly sedated in the first 48 h (Table [1](#Tab1){ref-type="table"}).

Early sedation depth and clinical outcomes {#Sec17}
------------------------------------------

Kaplan-Meier estimates showed that the patients who were deeply sedated at 48 h had a significantly longer time to extubation (log-rank *P* = 0.008) (Fig. [2](#Fig2){ref-type="fig"}) and higher hospital (log-rank *P* = 0.004) and 180-day mortality (log-rank *P* = 0.001) (Fig. [3](#Fig3){ref-type="fig"}). Univariate analysis showed that time to delirium after 48 h was also significantly shorter with early deep sedation (OR 0.64 95 % CI 0.57--0.73, *P* \< 0.001).Fig. 2Kaplan-Meier curves for time to extubation. Time to extubation was significantly longer amongst patients who were deeply sedated early compared with those that were not. Median (IQR) time to extubation was 3.95 (2.7--6.9) versus 6.69 (4--11.7) days (log-rank *P* \< 0.008)Fig. 3Kaplan-Meier curves for 180-day mortality. Those who were deeply sedated early (first 48 h) showed a significant increase in risk of death at 6 months (log-rank *P* = 0.001) compared with patients who were not deeply sedated

Multivariable Cox proportional hazard regression, adjusted for relevant covariates (Table [3](#Tab3){ref-type="table"}), showed that the occurrence of every additional RASS in the −3 to −5 range was independently associated with a reduced chance of shorter time to extubation (HR 0.93, 95 % CI 0.89--0.97, *P* = 0.0001), hospital death (HR 1.11, 95 % CI 1.04--1.18, *P* \< 0.001) and 180-day mortality (HR 1.10, 95 % CI 1.04--1.15, *P* = 0.002). Trend analysis using the Cochran-Mantel-Haenszel test showed that these associations were approximately linear (0.03). Early deep sedation was not associated with time to delirium occurring after 48 h (HR 0.98, *P* = 0.46).Table 3Multivariable proportional hazard Cox regression of time to extubation, delirium and 180-day mortality versus early sedation depth (RASS −3 to −5) as primary exposure variableTime to extubationDelirium after 48 h180-Day mortalityHR95 % CI*P*HR95 % CI*P*HR95 % CI*P*RASS −3 to −5^a^0.930.89--0.960.00010.980.94--1.030.461.101.04--1.150.0002APACHE II^b^0.960.94--0.980.0010.980.96--1.010.221.020.10--1.050.08Age1.000.99--1.010.771.011.00--1.030.041.021.00--1.030.01Male0.840.61--1.160.291.370.92--2.040.120.750.50--1.140.17Operative1.220.74--2.040.431.100.60--1.030.750.560.26--1.210.14Elective0.990.54--1.790.961.310.65--2.640.440.830.32--2.130.70Cardiac^c^0.840.47--1.500.561.170.59--2.320.662.220.92--5.360.07Respiratory^c^0.820.51--1.310.410.940.51--1.730.841.140.57--2.290.71Sepsis^c^0.970.59--1.600.911.220.65--2.310.541.220.59--2.500.60Gastrointes^c^0.610.33--1.120.110.940.46--1.900.862.421.02--5.750.04Vasopressors1.090.73--1.640.671.150.70--1.940.541.420.81--2.470.22Dialysis^d^0.530.32--0.860.011.030.60--1.760.920.940.94--2.450.09^a^For every additional RASS in deep sedation, chance of achieving the desired outcome (shorter time to extubation) was reduced by 7 % (4--11 %)^b^Acute Physiologic Assessment and Chronic Health Evaluation II^c^APACHE III admission diagnostic codes^d^Vasopressors and any form of dialysis within the first 48 h

Multivariable analysis with hospital mortality showed that early deep sedation (HR 1.13, 95 % CI 1.06--1.20, *P* \< 0.0001), APACHE II (HR 1.04, 95 % CI 1.00--1.08, *P* = 0.04) and a cardiac admission diagnosis (HR 3.51, 95 % CI 1.31--9.44, *P* = 0.01) were associated with hospital mortality.

Adjusted multivariable analysis also showed that the cumulative dose of midazolam in the first 48 h was associated with the RASS −3 to −5, but it was not associated with time to extubation, delirium or death. The cumulative dose of dexmedetomidine in the first 48 h, however, was significantly associated with delayed time to delirium occurring after 48 h (HR 1.41 95 % CI 1.13--1.76, *P* = 0.002).

Discussion {#Sec18}
==========

Main findings {#Sec19}
-------------

We identified a significant independent relationship between the intensity of sedation in the first 48 h (early) after initiation of mechanical ventilation and important clinical outcomes. Early deep sedation was independently associated with time to extubation and mortality. The occurrence of every additional RASS assessment in the deep sedation range was associated with a 13 % increase in the risk of death at hospital discharge (and 10 % at 6 months) and a 7 % delay in extubation (8.5 h). All these associations remained significant after adjusting for multiple covariates including sedative choice, admission diagnosis and severity of illness.

We also found that midazolam and morphine were the most commonly used agents for sedation and analgesia in Malaysian ICUs for patients ventilated for longer than 24 h, and the use of propofol was less frequent.

Other studies on sedation-related outcomes {#Sec20}
------------------------------------------

Our findings are consistent with findings of the ANZ SPICE study \[[@CR15]\] cohort and lend strong support to the notion that early deep sedation is an important and potentially modifiable risk factor for delayed time to extubation and increased mortality. Furthermore, our results suggest that these findings are neither confined to an ANZ ICU model of care nor determined by a particular sedative regimen. Thus, it is plausible that these findings are generalisable to a wider intensive care setting and that early deep sedation may be a global problem associated with poor outcome.

Patients enrolled in this cohort have similar characteristics to patients recruited in the ANZ SPICE study \[[@CR15]\] and in other observational \[[@CR20]\] and interventional studies \[[@CR21], [@CR22]\] with a high APACHE II score and primarily medical diagnoses with standard ICU interventions. The intensity of sedation depth reported at enrolment, early and throughout the study period is comparable to that reported in the ANZ SPICE \[[@CR15]\] study. All of this provides external validity and confidence that our findings may be applicable to similar cohorts.

Randomised trials of sedation practice have largely ignored this early period following initiation of mechanical ventilation and do not account for sedation practice and sedation depth prior to randomisation. In the largest sedation trials published so far, including the most recent randomised twin trials of sedation \[[@CR23], [@CR24]\], patients were randomised up to 72--96 h after ICU admission, potentially limiting the full treatment effect of the interventions tested.

Our study is the first to report the incidence of delirium in Malaysian ICUs. Although the CAM-ICU was only assessed during light sedation, 44 % of patients developed an episode of delirium. It is possible that delirium was underdiagnosed in our cohort; however, our patients were on average a few years younger than those in ANZ SPICE, inferring a lower risk of delirium. Although reduced sensitivity of the CAM-ICU has been reported \[[@CR25], [@CR26]\], delirium was methodologically and diligently assessed in our cohort by trained research and study staff. While sedative induced coma is believed to increase the risk of delirium \[[@CR27]\], we did not find early deep sedation or the cumulative dose of sedative agents to independently predict time to delirium. Dexmedetomidine given in the first 48 h, however, independently predicted delayed time to delirium occurring after 48 h.

Studies of sedation depth {#Sec21}
-------------------------

Reducing overall deep sedation has been shown to improve a variety of clinical outcomes. Strategies to reduce sedation depth included sedation interruption \[[@CR5]\], protocolised sedation \[[@CR6], [@CR8], [@CR28]\] and analgo-sedation \[[@CR7]\]. All appear to lead to shorter ventilation time, attenuation of delirium and trend to reduced mortality. It is important, however, to implement strategies to reduce sedation depth early after initiation of mechanical ventilation. This would be more challenging in the context of a randomised clinical trial.

The practice of daily sedation interruption was not common in our cohort. Multiple reports \[[@CR21], [@CR22], [@CR29]\] questioned the utility of routine sedation interruption where sedation algorithms are routinely used.

Our study supports the need for an adequately powered process of care sedation trial that addresses the problem of early deep sedation. This can be achieved through early delivery of interventions, which are likely to reduce the intensity of early and subsequent sedation while providing comfort and safety to patients. Such interventions may combine the use of agents known to promote light cooperative sedation such as propofol \[[@CR30]\] or dexmedetomidine \[[@CR23], [@CR24]\] with targeted light sedation. Importantly, future trials should assess long-term patient-centred outcomes such as mortality and cognitive function as the main outcomes.

Strengths and limitations {#Sec22}
-------------------------

The primary strengths of our study were the detailed and comprehensive assessment of patients from ICU admission (including the crucial first 48 h) to 28 days and an 180-day follow-up. This is the first study of this nature to be conducted outside the developed world; however, the study was supported by an experienced research methods centre and centrally coordinated and monitored; thus, the data quality was high. Robust statistical methods assessing time-to-event analysis using multivariate Cox proportional hazard regression adjusting for a priori selected covariates were used. Cohort studies, however, cannot establish causation, and unmeasured confounders could not be adjusted for in the statistical model.

Conclusion {#Sec23}
==========

In mechanically ventilated critically ill patients with mainly medical ICU admission diagnoses, the intensity of sedation in the first 48 h after initiation of mechanical ventilation was independently associated with time to extubation and mortality. These findings strengthen the premise that early sedation depth is a potentially modifiable target to improve important clinical outcomes and a universal problem in intensive care sedation worldwide. Future sedation trials should account for the choice of sedative agents and sedative delivery shortly after initiation of mechanical ventilation.

Appendix {#Sec24}
========

Participating centers and co-investigators {#Sec25}
------------------------------------------

University of Malaya: Dr. KK Wong, Dr. Suresh Venugopal, Dr. Vineya Rai, Dr. Mohd Shahnaz, Vimala Ramoo (Nurse Lecturer). National Heart Institute: Dr. Smitha Jose, Dr. Ozlem Ozturk, SN Zuraida Ramlee, Staff Nurse Bong Siu Foon, Staff Nurse Rohana Amran. Hospital Melaka: Dr. R.K. Anusha Narula, Dr. Erin Shazrin Md Ramly, Dr. Khalidah Abdul Hapiz, Dr. Lim I-Liang, Dr. Mohamad Hafiz Che Morad. Hospital Raja Perempuan Zainab II: Dr. Mohd Nazri Ali, Dr. H. Noor Raihan, Sister I. Azizum, Staff Nurse Y. Suzana, Staff Nurse H. Haryati. Kuala Lumpur General Hopsital: Staff Nurse S. Salmi Zawati, Staff Nurse J. Nur Ismee. Hospital Queen Elizebeth: Dr. Mohd Ashraf Zulkarnain. Hospital University Sains Malaysia: Assoc. Prof. Dr. Mahamarowi Omar, Dr. Siti Aisah Omar, Sister Rokian Ismail, Staff Nurse Norhamilah Hassan, Staff Nurse Zanariah Zakaria. Sarawak General Hospital: Dr. Sanah Mohtar, Dr. Marina Ahmad, Staff Nurse Winnie Suai, Staff Nurse Wong Ai Li, Staff Nurse Jong Siaw Lan. Hospital Sultanah Bahiyah: Dr. S. Siti Rohayah. Dr. Fitriah Mahadir, Staff Nurse Teoh Shook Lian, Staff Nurse Maryam Md Zain, Staff Nurse Noorasmah Ahmad. Hospital Sultanah Aminah: Dr. K. Mahazir, Staff Nurse A'ishah Abu Bakar. Penang General Hospital: Dr. Ho Wing Nan, Sister Tan Ai Ping, Sister Chin Lai Ngan, Dr. Lim Chiew Har, Dato Dr. Jahizah Hassan.

Participating centers and co-investigators are listed in the [Appendix](#Sec24){ref-type="sec"}.
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